Micromon’s DNA sequencing service is one of the key core facilities in Australia and has a nationwide reputation for its high quality data and reliable, customer-focused service. Micromon has an established high-throughput sequencing facility utilising Illumina Next-generation platform technology.

Encompasses and uses the CSIRO Biomolecular Interaction Facility and the CSIRO Bio21 Crystallisation Centre to screen libraries of fragments as the first step towards rational drug design

The MCRI GRF has collections of three PAC/BAC libraries; RPCI-1 Human PAC library, RPCI-11 Human Male BAC Library and RPCI-23 Female (C57BL/6J) Mouse BAC Library.

This shared resource – incorporating the AAHL Biosecurity Microscopy Facility (ABMF) – provides world-class infrastructure and related technology platforms for researchers conducting projects requiring a high biocontainment/biosecure environment.

High content screening is a sophisticated, state-of-the-art method used to identify modulations of cell biology and develop new therapeutics. The new High Content Cell Discovery and Screening Facility (HCSF) based at MIMR combines the advantages of high content screening with the development of genome-wide RNAi libraries and robotics to facilitate [...]

The Molecular Genomics Core Facility encompasses both the Microarray Core facility and the Next Generation DNA Sequencing Core Facility. For both facilities, services to external researchers are offered when spare capacity allows. Microarray We offer both full and partial services to researchers who wish to use Affymetrix Gene Expression arrays [...]

The HTCS Facility houses a Lead Discovery library currently containing ~200,000 compounds and robotics platforms to screen these small molecule chemical entities against biological targets of interest for drug discovery or for chemical biology outcomes. It has two core automation systems, the Hamilton MicroSTAR and PerkinElmer Minitrak IX systems as [...]

A member of the RNAi Global Initiative, the Functional Genomics Group at the Peter MacCallum Cancer Centre is open to the Australian medical research community for the purpose of providing access to both small interfering (siRNA) and lentiviral-based short hairpin RNAi (shRNAmir) gene knockdown screens for functional genomics studies.